The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2Rγ chain expression

Blood

Volumn 89, Issue 9, 1997, Pages 3402-3411

  Bosco, Maria Caria ^a,c   Rottschafer, Sandra ^a   Taylor, Lynn S ^b   Ortaldo, John R ^b   Longo, Dan L ^b   Espinoza Delgado, Igor ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BRYOSTATIN 1; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0030905835     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3402     Document Type: Article

References (59)

1. Pettit GR, Herald SL, Doubek DL, Arnold E, Clardy J: Isolation and structure of bryostatin-1. J Am Chem Soc 104:6846, 1982
2. Kraft AS: Bryostatin 1: Will the oceans provide a cancer cure? J Natl Cancer Inst 85:1790, 1993
3. Stone RM, Sariban E, Pettit GR, Kufe DW: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72:208, 1988
4. Berkow RL, Kraft AS: Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 131:1109, 1985
5. Lewin NE, 'Dell'Aquila ML, Pettit GR, Blumberg PM, Warren BS: Binding of 3H bryostatin 4 to protein kinase C. Biochem Pharmacol 43:2007, 1992
6. Smith JB, Smith L, Pettit GR: Bryostatins: Potent, new mitogens that mimic phorbol ester tumor promotors. Biochem Biophys Res Commun 132:939, 1985
7. Ramsdell JS, Pettit GR, Tashjian AHJ: Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells. J Biol Chem 261:17073, 1986
8. Kraft AS, Reeves JA, Ashendel CL: Differing modulation of protein kinase C by bryostatin and phorbol esters in JB6 mouse epidermal cells. J Biol Chem 263:8437, 1988
9. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R, Yuspa SH: Bryostatin-1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8:1343, 1987
10. Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of Bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity. Cancer Res 52:101, 1992
11. Schuchter L, Esa AH, May WS, Laulis MK, Pettit GR, Hess AD: Successful treatment of murine melanoma with Bryostatin-1. Cancer Res 51:682, 1991
12. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS: Bryostatin-1, a unique biologic response modifier: Antileukemic activity in vitro. Blood 75:1319, 1990
13. Lilly M, Brown C, Pettit G, Kraft A: Bryostatin-1: A potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia 5:283, 1991
14. Scheid C, Prendiville J, Jayson G, Crowther D, Fox B, Pettit GR, Stern PL: Immunomodulation in patients receiving intravenous Bryostatin-1 in a phase I clinical study: Comparison with effects of Bryostatin-1 on lymphocyte function in vitro. Cancer Immunol Immunother 12:223, 1994
15. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR: A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68:418, 1993
16. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rocke« H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL: Phase 1 study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J Natl Cancer Inst 85:1812, 1993
17. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL: Differential effects of bryostatin-1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res 17:1, 1993
18. Asiedu C, Biggs J, Liily M, Kraft AS: Inhibition of leukemia cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 55:3716, 1995
19. Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammed RM, Al-Katib A: The bcl-2 and p53 oncoproteins can be modulated by bryostatin-1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 6:392, 1995
20. Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G: The antineoplastic bryostatins affect human basophils and mast cells differently. Blood 85:1272, 1995
21. Berkow RL, Schlabach L, Dodson R, Benjamin WH Jr, Pettit GR, Rustagi P, Kraft AS: In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 53:2810, 1993
22. Hess AD, Silanskis MK, Esa AH, Pettit GR, May WS: Activation of human T lymphocytes by bryostatin. J Immunol 141:3263, 1988
23. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD: Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548, 1992
24. Drexler HG, Gignac SM, Pettit GR, Hoffbrand AV: Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation. EurJ Immunol 20:119, 1990
25. Mohr H, Pettit GR, Plessing-Menze A: Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 175:420, 1987
26. Bonta IL, Ben-Efraim S: Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 54:613, 1993
27. Adams DO, Hamilton TA: The cell biology of macrophage activation. Annu Rev Immunol 2:283, 1984
28. Unanue ER: Antigen-presenting function of the macrophage. Annu Rev Immunol 2:395, 1984
29. Unanue ER, Allen PM: The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236:551, 1987
30. Philip R, Epstein LB: Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323:86, 1986
31. Feinman R, Henriksen-Destefano M, Tsujimoto M, Vilcek J: Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 138:635, 1987
32. Van Snick J: Interleukin-6: An overview. Annu Rev Immunol 8:253, 1990
33. Ichinose Y, Tsao JY, Fidler IJ: Destruction of tumor cells by monokines released from activated human blood monocytes: Evidence for parallel and additive effects of IL-1 and TNF. Cancer Immunol Immunother 27:7, 1988
34. Mule' JJ, Mclntosh JK, Jablons DM, Rosenberg SA: Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 171:629, 1990
35. Djew JY, Matsushima K, Oppenheim JJ, Shiotsuki K, Blanchard DK: Functional activation of human neutrophils by recombinant
36. monocyte-derived neutrophil chemotactic factor/IL-8. J Immunol 144:2205, 1990
37. Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ: T lymphocyte recruitment by interleukin-8 (IL-8). J Clin Invest 97:1931, 1996
38. Varesio L, Cox GW, Pulkki K, Musso T, Latham PS, Gusella GL, Espinoza-Delgado I: Activation of macrophages and monocytes by interferon-gamma and interIeukin-2, in Klostergaard Ja G. (ed): Mononuclear Phagocytes in Cell Biology. Boca Raton, FL, CRC, 1993, p 119
39. Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L: Interleukin-2 and human monocyte activation. J Leukoc Biol 57:1995
40. Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl LM, Katona IM: Monocyte interleukin-2 receptor gene expression and interleukin-2 augmentation of microbicidal activity. J Immunol 139:1342, 1987
41. Malkovsky M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers W: Recombinant interleukin 2 directly augments the cytotoxicity of human monocytes. Nature 325:262, 1987
42. Remick DG, Larrick JW, Nguyen DT, Kunkel SL: Stimulation of prostaglandin E2 and thromboxane B2 production by human monocytes in response to interleukin-2. Biochem Biophys Res Commun 147:86, 1987
43. Stevenson HC: Isolation of human mononuclear leukocyte subsets by counter current centrifugal elutriation. Methods Enzymol 108:242, 1984
44. Wang AS, Lu D, Mark DF: Site-specific mutagenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues. Science 224:1431, 1984
45. Musso T, Espinoza-Delgado I, Pulkki K, Gusella GL, Longo DL, Varesio L: IL-2 induces IL-6 production in human monocytes. J Immunol 148:795, 1992
46. Bosco MC, Pulkki K, Rowe TK, Zea AH, Musso T, Longo DL, Varesio L, Espinoza-Delgado I: IL-4 inhibits IL-2-induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 binding and IL-2 receptor beta/gamma chain expression. J Immunol 155:1411, 1995
47. Gusella GL, Musso T, Bosco MC, Espinoza-Delgado 1, Matsushima K, Varesio L: Interleukin-2 upregulates, but interferongamma suppresses, interleukin-8 expression in human monocytes. J Immunol 151:2725, 1993
48. Espinoza-Delgado I, prtaldo JR, Winkler-Pickett R, Sugamura K, Varesio L, Longo DL: Expression and role of p75 interleukin 2 receptor on human monocytes. J Exp Med 171:1821, 1990
49. Bosco MC, Espinoza-Delgado I, Schwabe M, Gusella LG, Longo DL, Sugamura K, Varesio L: Regulation by Interleukin-2 (IL-2) and Interferon-gamma (IFN-gamma) of IL-2R-gamma gene expression in human monocytes. Blood 83:2995, 1994
50. Bosco MC, Espinoza-Delgado I, Schwabe M, Leonard WJ, Longo DL, Varesio L: The gamma chain of the IL-2R is expressed in human monocytes and modulated by IL-2, IFN-gamma, and TGF-beta. Blood 83:3462, 1994
51. Tamaoki T: Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol 201:340, 1991
52. May WS, Sharkis SJ, Esa AH, Gebbia V, Kraft AS, Pettit GR, Sensenbrenner LL: Antineoplastic bryostatins are multipotential stimulators of human hematopoetic progenitor cells. Proc Natl Acad Sci USA 84:8483, 1987
53. Steube KG, Drexler HG: The protein kinase C activator bryostatin-1 induces the rapid release of TNF alpha from mono-mac-6 cells. Biochem Biophys Res Commun 214:1197, 1995
54. Grant S, Poplin B, Bear HD, Tombes MB, Kyle BM, Roberts J: Phase Ib pharmacokinetic and pharmacodynamic trial of the protein kinase C activator bryostatin-1. Proc AACR 37:1146, 1996 (abstr)
55. Tosato G, Jones KD: Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 75:1305, 1990
56. Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM: The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin 1. Cancer Res 56:2105, 1996
57. Gebbia V, Testa A, Pettit GR, Sensenbrenner LL, May WS: Antineoplastic agent bryostatin-1 promotes growth of normal murine haematopoietic progenitors in vivo. Cell Pharmacol 1:31, 1993
58. Grant S, Taylor R, Pettit GR, Lin PS: The macrocyclic lactone protein kinase C activator, Bryostatin-1, either alone or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation. Blood 83:663, 1994
59. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Nakamura M, Takeshita T: The common gamma-chain for multiple cytokine receptors. Adv Immunol 59:225, 1995